title: The effect of clofibrate on hyperbilirubinemia of term neonates.
abstract: Clofibrate is a glucuronosyl transferase inducer that has been proposed to increase the elimination of bilirubin in neonates with hyperbilirubinemia. This study was conducted to determine the therapeutic effect of clofibrate in term neonates with non-hemolytic jaundice. This study was conducted on 52 newborns with pathologic unconjugated jaundice in Qazvin children hospital. Newborns divided randomly in two groups. Case group treated with clofibrate and intensive phototherapy, while control group treated only with intensive phototherapy. Serum bilirubin level was measured before and 6, 12, 24 and 48 hours after treatment. Results were compared and analyzed. The mean serum level of bilirubin before treatment in the case and control groups were 20.78 ± 2.38 and 20.52 ± 2.44 mg/dl, respectively (P=0.69). The mean serum level of bilirubin in 6, 12, 24 and 48 hours after treatment in the case group were 18.20 ± 2.20, 14.70 ± 2.06, 10.72 ± 2.40 and 8.90 ± 0.83 mg/dl , respectively. These values in control group were 18.26 ± 2.42, 15.36 ± 2.59, 12.29 ± 2.28 and 10.23 ± 1.50 mg/dl, respectively. There was significant difference between two groups regarding mean serum level of bilirubin 24 hours (P=0.019) and 48 hours after treatment (P=0.005). In conclusion, clofibrate was effective in reducing neonatal jaundice and its effect appeared 24 hours after treatment.
authors.affiliation: Department of Pediatrics, Qazvin University of Medical Sciences, Iran. Drmhabibi@yahoo.com
authors.forename: Morteza
authors.initials: M
authors.lastname: Habibi
authors.forename: Abolfazl
authors.initials: A
authors.lastname: Mahyar
authors.forename: Parviz
authors.initials: P
authors.lastname: Ayazi
authors.forename: Farzad
authors.initials: F
authors.lastname: Ahmadabadi
authors.forename: Amir
authors.initials: A
authors.lastname: Javadi
mesh_terms: D001663:Bilirubin / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D051556:Hyperbilirubinemia, Neonatal / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D007231:Infant, Newborn; D007492:Iran; D008297:Male; D010789:Phototherapy; D016037:Single-Blind Method; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D002994:Clofibrate; D001663:Bilirubin